M Finke - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

M Finke

Showing results (171-180 of 180) with videos related to

Pageof 18

Sort By:

You have reached the last page of results.This site can display upto 180 results.

Haematologica|June 20, 2024

<i>ASXL1/TET2</i> genotype-based risk stratification outperforms <i>ASXL1</i> mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemiaClifford M Csizmar, Mark Gurney, Rashmi Kanagal-Shamanna, et al.

Leukemia|September 13, 2019

Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patientsAbhishek A Mangaonkar, David M Swoboda, Giacomo Coltro, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2023

Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMMLChristopher T Letson, Maria E Balasis, Hannah Newman, et al.

Blood Advances|December 4, 2024

Single-cell multiomics reveal divergent effects of DNMT3A- and TET2-mutant clonal hematopoiesis in inflammatory responseWazim Mohammed Ismail, Jenna A Fernandez, Moritz Binder, et al.

Blood Advances|January 7, 2026

Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopeniasTalha Badar, Ludovica Marando, Eric Latorre-Crespo, et al.

Cancer Discovery|August 27, 2024

RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal HematopoiesisNana Adjoa Ben-Crentsil, Wazim Mohammed Ismail, Maria E Balasis, et al.

Blood Advances|July 11, 2025

Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Sanam Loghavi, Ziyi Li, et al.

Leukemia|June 24, 2025

Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypesClifford M Csizmar, Anuya Natu, Mark Gurney, et al.

Blood|May 7, 2025

BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic LeukemiaAyalew Tefferi, Saubia Fathima, Maymona Abdelmagid, et al.

Blood Cancer Discovery|January 26, 2026

Incorporation of genomic determinants improves diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Chong Wu, Juan Jose Rodriguez-Sevilla, et al.

Pageof 18

Search research articles

Showing results (171-180 of 180) with videos related to

Sort By:

Pageof 18

You have reached the last page of results.This site can display upto 180 results.

Haematologica|June 20, 2024

Leukemia|September 13, 2019

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2023

Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMMLChristopher T Letson, Maria E Balasis, Hannah Newman, et al.

Blood Advances|December 4, 2024

Single-cell multiomics reveal divergent effects of DNMT3A- and TET2-mutant clonal hematopoiesis in inflammatory responseWazim Mohammed Ismail, Jenna A Fernandez, Moritz Binder, et al.

Blood Advances|January 7, 2026

Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopeniasTalha Badar, Ludovica Marando, Eric Latorre-Crespo, et al.

Cancer Discovery|August 27, 2024

RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal HematopoiesisNana Adjoa Ben-Crentsil, Wazim Mohammed Ismail, Maria E Balasis, et al.

Blood Advances|July 11, 2025

Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Sanam Loghavi, Ziyi Li, et al.

Leukemia|June 24, 2025

Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypesClifford M Csizmar, Anuya Natu, Mark Gurney, et al.

Blood|May 7, 2025

BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic LeukemiaAyalew Tefferi, Saubia Fathima, Maymona Abdelmagid, et al.

Blood Cancer Discovery|January 26, 2026

Incorporation of genomic determinants improves diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Chong Wu, Juan Jose Rodriguez-Sevilla, et al.

Pageof 18